{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:15:14Z","timestamp":1788642914576,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Self-Funded Plan Projects of Guangxi Health Commission","award":["Z-A20220418,Z-A20220414"],"award-info":[{"award-number":["Z-A20220418,Z-A20220414"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"abstract":"<jats:p>To explore the correlation between immune status, genetic profile, laboratory parameters, and staging in patients with newly diagnosed multiple myeloma (NDMM) and to investigate the clinical characteristics of these patients along with their associated risk factors. The clinical data of 135 patients with multiple myeloma (MM) admitted to the First Affiliated Hospital of Guangxi Medical University between March 2020 and December 2023 were retrospectively collected. These data were systematically organized to evaluate the staging status of patients, including the Durie-Salmon, International Staging System, Revised International Staging System, and mSMART 3.0 staging systems. Additionally, the study included analysis of peripheral blood T-lymphocyte subpopulations and Fluorescence In Situ Hybridization results. Laboratory indices were collected at the initial diagnosis of patients with MM prior to any treatment. These data were subsequently analyzed to ascertain their significance in staging patients with multiple myeloma. Among 135 patients with MM, N-terminal pro-brain natriuretic peptide (NT-proBNP) and lambda light chain (\u03bb light chain) levels were higher in patients with abnormal kidney function (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). NT-proBNP and \u03bb light chain levels can predict abnormal renal function in patients with NDMM. The \u03bb light chain levels were significantly higher in Zhuang patients than in Han patients (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Patients with high staging differed in total T cell percentages, CD8<jats:sup>+<\/jats:sup> cell percentages, T cells, CD3<jats:sup>+<\/jats:sup>\/CD4<jats:sup>-<\/jats:sup>\/CD8<jats:sup>-<\/jats:sup> double-negative cell percentages, CD8<jats:sup>+<\/jats:sup>T cells, age, NT-proBNP, and M protein levels (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). In addition, M protein levels and age were positively correlated with CD4<jats:sup>+<\/jats:sup>T cells and negatively correlated with CD8<jats:sup>+<\/jats:sup>T cells (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). CD8<jats:sup>+<\/jats:sup> T cells, age, NT-proBNP, M protein level, and cytogenetic abnormalities represent distinct aspects of immune status, tumor load, and cytogenetic status at the initial diagnosis of patients. These indices are closely associated with the clinical stage of patients and can be combined to assess the clinical stage of multiple myeloma patients after admission to the hospital. Additionally, NT-proBNP and \u03bb light chain levels play a role in predicting abnormal renal function in patients with NDMM.<\/jats:p>","DOI":"10.1097\/md.0000000000040710","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T21:02:22Z","timestamp":1732914142000},"page":"e40710","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7069-0015","authenticated-orcid":false,"given":"Zhenrui","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Guangxi Medical University, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-7670","authenticated-orcid":false,"given":"Yu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020.","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020.","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15_suppl","key":"R6-20250503","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2016.34.15_suppl.8017","article-title":"Clinical utility of the revised international staging system (RISS) in newly diagnosed multiple myeloma.","volume":"34","author":"Tandon","year":"2016","journal-title":"J Clin Oncol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2019-130092","article-title":"Significance of modified risk stratification Msmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.","volume":"134","author":"Garifullin","year":"2019","journal-title":"Blood"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma.","volume":"130","author":"Minnie","year":"2020","journal-title":"J Clin Invest"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma.","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project.","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jtct.2023.08.031","article-title":"Outcomes of autologous stem cell transplantation in patients with ultra-high-risk multiple myeloma.","volume":"29","author":"Pasvolsky","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13835","article-title":"Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.","volume":"109","author":"Spicka","year":"2022","journal-title":"Eur J Haematol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","article-title":"Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.","volume":"128","author":"Bochtler","year":"2016","journal-title":"Blood"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13325","article-title":"Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?","volume":"103","author":"Gran","year":"2019","journal-title":"Eur J Haematol"},{"key":"R16-20250503","first-page":"2950","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape.","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy.","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428194.2020.1751840","article-title":"Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma.","volume":"61","author":"Gu","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"1228004","DOI":"10.3389\/fimmu.2023.1228004","article-title":"High CD8+tumor-infiltrating lymphocytes indicate severe exhaustion and poor prognosis in angioimmunoblastic T-cell lymphoma.","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"816499","DOI":"10.3389\/fimmu.2021.816499","article-title":"Natural killer cells in the malignant niche of multiple myeloma.","volume":"12","author":"Venglar","year":"2022","journal-title":"Front Immunol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"748207","DOI":"10.3389\/fimmu.2021.748207","article-title":"NK cell reconstitution after autologous hematopoietic stem cell transplantation: association between NK cell maturation stage and outcome in multiple myeloma.","volume":"12","author":"Orrantia","year":"2021","journal-title":"Front Immunol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2018.10.005","article-title":"Translating the anti-myeloma activity of Natural Killer cells into clinical application.","volume":"70","author":"Fionda","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","article-title":"Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.","volume":"20","author":"Rueff","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"816005","DOI":"10.3389\/fimmu.2022.816005","article-title":"CD3+CD4-CD8- (Double-Negative) T cells in inflammation, immune disorders and cancer.","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-13-1672","article-title":"Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.","volume":"74","author":"Vallacchi","year":"2014","journal-title":"Cancer Res"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"941385","DOI":"10.3389\/fimmu.2022.941385","article-title":"CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions.","volume":"13","author":"Murayama","year":"2022","journal-title":"Front Immunol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/jpm13040666","article-title":"Characteristics and risk factors of ultra-high-risk patients with newly diagnosed multiple myeloma.","volume":"13","author":"Geng","year":"2023","journal-title":"J Pers Med"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"106750","DOI":"10.1016\/j.leukres.2021.106750","article-title":"Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: a retrospective analysis.","volume":"112","author":"Minakata","year":"2022","journal-title":"Leuk Res"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ndt\/gfz211","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry.","volume":"36","author":"Courant","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides.","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00277-021-04591-z","article-title":"N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution.","volume":"100","author":"Jimenez-Zepeda","year":"2021","journal-title":"Ann Hematol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"e12905","DOI":"10.1111\/eci.12905","article-title":"N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma.","volume":"48","author":"Pavo","year":"2018","journal-title":"Eur J Clin Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:02:30Z","timestamp":1746316950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":34,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040710","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}